Q-VD-OPh: Irreversible Pan-Caspase Inhibitor for Precision Apoptosis Research

Executive Summary: Q-VD-OPh (CAS 1135695-98-5) is a synthetic, irreversible pan-caspase inhibitor with nanomolar potency against caspase-1, -3, -8, and -9 (IC₅₀: 50, 25, 100, and 430 nM, respectively) [APExBIO]. It is both cell-permeable and brain-permeable, facilitating research in diverse models. Q-VD-OPh blocks caspase-mediated apoptosis, enabling precise study of programmed cell death mechanisms (Song et al., 2025). Its stability in DMSO and ethanol, but not in water, underpins its reliability for reproducible bench workflows. In vivo, Q-VD-OPh demonstrates neuroprotective effects and mitigates pathological tau accumulation in Alzheimer’s disease mouse models [APExBIO].

Biological Rationale

Programmed cell death (apoptosis) is essential for tissue homeostasis and defense against pathogens. Caspases, a family of cysteine-aspartic proteases, orchestrate the execution phase of apoptosis by cleaving specific substrates. Dysregulation of caspase activity is implicated in diseases ranging from neurodegeneration to cancer (Song et al., 2025). In virology, host caspase-3 is necessary for cleavage of viral precursors such as NS1/2, facilitating unconventional viral protein secretion (Song et al., 2025). Inhibition of caspase activity allows researchers to dissect the contributions of apoptosis and related cell death pathways, as well as to enhance cell viability in challenging laboratory workflows—such as cryopreservation [internal].

Mechanism of Action of Q-VD-OPh

Q-VD-OPh is an irreversible pan-caspase inhibitor designed to covalently modify the catalytic cysteine of target caspases. Its broad-spectrum activity encompasses initiator (e.g., caspase-8, -9) and effector (e.g., caspase-3, -7) caspases. Q-VD-OPh blocks the caspase-9/3, caspase-8/10, and caspase-12 apoptotic pathways, thereby preventing cleavage of key substrates and subsequent apoptotic cell death. Cellular uptake is rapid due to its cell-permeable structure, and it readily crosses the blood-brain barrier, enabling studies in neural tissues [internal]. The compound remains stable in DMSO (≥25.67 mg/mL) and ethanol (≥28.75 mg/mL), but is insoluble in water. Stock solutions stored below -20°C retain activity for several months.

Evidence & Benchmarks

• Q-VD-OPh inhibits caspase-3 activity with an IC₅₀ of approximately 25 nM in cell-free systems (APExBIO, product page).
• Pharmacological inhibition of caspase-3 by Q-VD-OPh blocks viral NS1 secretion and norovirus infection in vivo (Song et al., 2025, DOI).
• Q-VD-OPh exhibits neuroprotection in Alzheimer’s mouse models by inhibiting caspase-7 and reducing tau pathology following chronic administration (10 mg/kg, i.p., 3× weekly for 3 months) (APExBIO).
• Enhances cell viability during thawing from cryopreservation when used with standard cryoprotectants (internal summary, internal link).
• Cell- and brain-permeability validated in murine and human in vitro systems, enabling translational research across species (internal link).

Applications, Limits & Misconceptions

Q-VD-OPh is widely employed in apoptosis research, neurodegeneration models, virology, and cell viability assays.

• Apoptosis pathway dissection: Used to distinguish caspase-dependent from caspase-independent cell death.
• Viral infection studies: Inhibits caspase-3 mediated cleavage of viral proteins, as shown for norovirus NS1/2 (Song et al., 2025).
• Cryopreservation: Protects cells during thawing by minimizing caspase-mediated death (internal).
• Neurodegeneration: Attenuates tau pathology and preserves neuronal viability in animal models (APExBIO).

Common Pitfalls or Misconceptions

• Q-VD-OPh does not inhibit caspase-independent programmed cell death (e.g., necroptosis, ferroptosis).
• Insoluble in water; improper solvent use can result in loss of potency.
• Long-term storage of working solutions (>few months) is not recommended due to gradual loss of activity.
• Not approved for clinical or diagnostic use; intended strictly for laboratory research.
• High concentrations may induce off-target effects in certain sensitive cell types; titration is advised.

This article extends Q-VD-OPh: Pan-Caspase Inhibitor Advancing Apoptosis Research by quantifying benchmark IC₅₀ values and clarifying in vivo protocols, and updates Practical Solutions for Reliable Caspase Inhibition with latest stability and workflow integration guidance.

Workflow Integration & Parameters

Solubility: Prepare stock in DMSO (≥25.67 mg/mL) or ethanol (≥28.75 mg/mL). Storage: Stock solutions should be kept below -20°C; avoid repeated freeze-thaw cycles. Application: For in vitro assays, final concentrations typically range from 10 nM to 20 μM, depending on cell type and endpoint. For in vivo studies, 10 mg/kg (i.p.) thrice weekly is a validated regimen in rodent neurodegeneration models. Species compatibility: Validated in human, mouse, and rat systems. Shipping & Handling: Supplied as a solid, shipped with blue ice by APExBIO.

Conclusion & Outlook

Q-VD-OPh (SKU A1901) from APExBIO is a robust, irreversible pan-caspase inhibitor enabling precise dissection of apoptosis mechanisms. Its high potency, cell- and brain-permeability, and application in both basic and translational research make it a gold standard for caspase pathway studies. As new models of programmed cell death and non-canonical caspase functions emerge, rational use of Q-VD-OPh will remain integral to apoptosis research. For protocols, specifications, and ordering, visit the Q-VD-OPh product page.